RubrYc Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1M

RubrYc Therapeutics General Information

Description

Developer of novel biotherapeutic technologies designed to integrate chemistry and computation to discover and develop antibody-based drugs with epitope selectivity. The company's technologies decode protein interactions with the integration of data and biological science through molecular library synthesis, enabling bio-therapeutic partners to accelerate preclinical antibody discovery while minimizing the risks associated with current drug discovery paradigms.

Contact Information

Website
www.rubryc.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RubrYc Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-Sep-2022 $1M Completed Generating Revenue
4. Early Stage VC (Series A2) 25-Apr-2021 Completed Generating Revenue
3. Early Stage VC 22-Jul-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator $10M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 09-Apr-2018 $10M $10M Completed Pre-Clinical Trials
To view RubrYc Therapeutics’s complete valuation and funding history, request access »

RubrYc Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A
Founders 1,480,079 $0.000100 8% $0.71 $0.71 1x $0.71 3.3%
To view RubrYc Therapeutics’s complete cap table history, request access »

RubrYc Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel biotherapeutic technologies designed to integrate chemistry and computation to discover and develop a
Drug Discovery
San Carlos, CA
11 As of 2022

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RubrYc Therapeutics Competitors (1)

One of RubrYc Therapeutics’s competitors is Immune-Onc Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
You’re viewing 1 of 1 competitors. Get the full list »

RubrYc Therapeutics Patents

RubrYc Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022119863-A1 Generalized scaffolds for polypeptide display and uses thereof Inactive 01-Dec-2020
WO-2022104009-A1 Cd25 antibodies Inactive 13-Nov-2020
WO-2020242766-A1 Machine learning-based apparatus for engineering meso-scale peptides and methods and system for the same Inactive 31-May-2019
JP-2022535769-A Machine learning-based apparatus for manipulating mesoscale peptides and methods and systems therefor Active 31-May-2019
WO-2020242765-A1 Meso-scale engineered peptides and methods of selecting Inactive 31-May-2019 G16B40/20
To view RubrYc Therapeutics’s complete patent history, request access »

RubrYc Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RubrYc Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boryung (United States) PE/Buyout Minority
MBC BioLabs Accelerator/Incubator Minority
Paladin Capital Group Venture Capital Minority
Third Point Ventures Venture Capital Minority
VC23 Investors Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

RubrYc Therapeutics FAQs

  • When was RubrYc Therapeutics founded?

    RubrYc Therapeutics was founded in 2017.

  • Where is RubrYc Therapeutics headquartered?

    RubrYc Therapeutics is headquartered in San Carlos, CA.

  • What is the size of RubrYc Therapeutics?

    RubrYc Therapeutics has 11 total employees.

  • What industry is RubrYc Therapeutics in?

    RubrYc Therapeutics’s primary industry is Drug Discovery.

  • Is RubrYc Therapeutics a private or public company?

    RubrYc Therapeutics is a Private company.

  • What is the current valuation of RubrYc Therapeutics?

    The current valuation of RubrYc Therapeutics is .

  • What is RubrYc Therapeutics’s current revenue?

    The current revenue for RubrYc Therapeutics is .

  • How much funding has RubrYc Therapeutics raised over time?

    RubrYc Therapeutics has raised $19.8M.

  • Who are RubrYc Therapeutics’s investors?

    Boryung (United States), MBC BioLabs, Paladin Capital Group, Third Point Ventures, and VC23 Investors are 5 of 6 investors who have invested in RubrYc Therapeutics.

  • Who are RubrYc Therapeutics’s competitors?

    Immune-Onc Therapeutics is a competitor of RubrYc Therapeutics.

  • When was RubrYc Therapeutics acquired?

    RubrYc Therapeutics was acquired on 21-Sep-2022.

  • Who acquired RubrYc Therapeutics?

    RubrYc Therapeutics was acquired by iBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process